$GH (Guardant Health) — 8-K: Guardant Health grants co-CEOs 465,413 performance-based PSUs tied to relative TSR

Guardant Health's board approved grants of 465,413 target PSUs to each co-CEO, Helmy Eltoukhy and AmirAli Talasaz, on November 2, 2026. Twenty-five percent of the target PSUs vest on relative TSR over a three-year period ending May 31, 2029, and 75% over a five-year period ending May 31, 2031, with payouts ranging from zero below the 40th percentile to 250% of target at the 90th percentile. Payouts are capped at 100% of target if absolute TSR is negative, and no more than 250% of target PSUs may vest. The company cited 275% total shareholder return over the last three fiscal years.

Guardant Health's board approved grants of 465,413 target PSUs to each co-CEO, Helmy Eltoukhy and AmirAli Talasaz, on November 2, 2026. Twenty-five percent of the target PSUs vest on relative TSR over